Senate committee calls for major drug review

Stepping boldly outside its terms of reference, a Senate Committee investigating new cancer drugs in Australia, has called for a comprehensive review of the registration and subsidisation system.

Although tasked only with looking at access to cancer drugs, the Committee say their findings have broader application and that a thorough review of the TGA registration and PBS listing process will address the concerns of all patients who rely on the PBS.